T-cell therapy using interleukin-21-primed cytotoxic T-cell lymphocytes combined with cytotoxic T-cell lymphocyte antigen-4 blockade results in long-term cell persistence and durable tumor regression

Journal of Clinical Oncology

Volumn 34, Issue 31, 2016, Pages 3787-3795

  Chapuis, Aude G ^a   Roberts, Ilana M ^a   Thompson, John A ^a   Margolin, Kim A ^a   Bhatia, Shailender ^a   Lee, Sylvia M ^a   Sloan, Heather L ^a   Lai, Ivy P ^a   Farrar, Erik A ^a   Wagener, Felecia ^a   Shibuya, Kendall C ^a   Cao, Jianhong ^a   Wolchok, Jedd D ^b   Greenberg, Philip D ^a   Yee, Cassian ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ALT 801; ANTINEOPLASTIC AGENT; B RAF KINASE INHIBITOR; CD27 ANTIGEN; CD28 ANTIGEN; CHEMOKINE RECEPTOR CCR7; CISPLATIN; CYCLOPHOSPHAMIDE; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; GAMMA INTERFERON; GLYCOPROTEIN GP 100; HLA A2 ANTIGEN; INTERLEUKIN 2; INTERLEUKIN 21; INTERLEUKIN 7 RECEPTOR; IPILIMUMAB; KI 67 ANTIGEN; L SELECTIN; MELACINE; MELAN A; MELANOMA ANTIGEN 3; MONOCLONAL ANTIBODY; MONOPHENOL MONOOXYGENASE; NY ESO 1 ANTIGEN; PREDNISONE; STEROID; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG; VEMURAFENIB; IMMUNOLOGICAL ANTINEOPLASTIC AGENT; INTERLEUKIN DERIVATIVE;

ADOPTIVE IMMUNOTHERAPY; ADOPTIVE TRANSFER; ADULT; AGED; ANTIGEN EXPRESSION; ANTIGEN SPECIFICITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER PATIENT; CANCER PROGNOSIS; CANCER STAGING; CANCER SURVIVAL; CD8+ T LYMPHOCYTE; CELL SELECTION; CHILL; CLINICAL ARTICLE; CYTOKINE RELEASE SYNDROME; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; DIARRHEA; DRUG EFFICACY; DRUG FEVER; DRUG MEGADOSE; DRUG SAFETY; FEMALE; FEVER; HUMAN; HYPERTRANSAMINASEMIA; HYPOPHYSITIS; IMMUNOPATHOLOGY; IMMUNOPHENOTYPING; LOW DRUG DOSE; LYMPHOCYTOPENIA; MACULOPAPULAR RASH; MALE; MEMORY T LYMPHOCYTE; METASTATIC MELANOMA; MIDDLE AGED; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; NAUSEA; PATIENT MONITORING; PRIORITY JOURNAL; RESPONSE EVALUATION CRITERIA IN SOLID TUMORS; SINGLE DRUG DOSE; STEROID THERAPY; SYSTEMIC THERAPY; TREATMENT RESPONSE; TUMOR REGRESSION; IMMUNOLOGY; MELANOMA; MULTIMODALITY CANCER THERAPY; PROCEDURES; REMISSION;

ADULT; AGED; ANTINEOPLASTIC AGENTS, IMMUNOLOGICAL; COMBINED MODALITY THERAPY; CTLA-4 ANTIGEN; FEMALE; HUMANS; IMMUNOTHERAPY, ADOPTIVE; INTERLEUKINS; IPILIMUMAB; MALE; MELANOMA; MIDDLE AGED; REMISSION INDUCTION; T-LYMPHOCYTES, CYTOTOXIC;

EID: 84993985148     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2015.65.5142     Document Type: Article

References (49)

1. Stromnes IM, Schmitt TM, Chapuis AG, et al: Readapting T cells for cancer therapy: From mouse models to clinical trials. Immunol Rev 257:145-164, 2014
2. Rosenberg SA, Yang JC, Sherry RM, et al: Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy. Clin Cancer Res 17:4550-4557, 2011
3. Yang JC: The adoptive transfer of cultured T cells for patients with metastatic melanoma. Clin Dermatol 31:209-219, 2013
4. Chapuis AG, Thompson JA, Margolin KA, et al: Transferred melanoma-specific CD8+ T cells persist, mediate tumor regression, and acquire central memory phenotype. Proc Natl Acad Sci USA 109: 4592-4597, 2012
5. Hunder NN, Wallen H, Cao J, et al: Treatment of metastatic melanoma with autologous CD4+ T cells against NY-ESO-1. N Engl J Med 358: 2698-2703, 2008
6. Wallen H, Thompson JA, Reilly JZ, et al: Fludarabine modulates immune response and extends in vivo survival of adoptively transferred CD8 T cells in patients with metastatic melanoma. PLoS One 4: e4749, 2009
7. Yee C, Thompson JA, Byrd D, et al: Adoptive T cell therapy using antigen-specific CD8+ T cell clones for the treatment of patients with metastatic melanoma: In vivo persistence, migration, and antitumor effect of transferred T cells. Proc Natl Acad Sci USA 99:16168-16173, 2002
8. Chapuis AG, Ragnarsson GB, Nguyen HN, et al: Transferred WT1-reactive CD8+ T cells can mediate antileukemic activity and persist in posttransplant patients. Sci Transl Med 5:174ra27, 2013
9. Klebanoff CA, Gattinoni L, Restifo NP: Sorting through subsets: Which T-cell populations mediate highly effective adoptive immunotherapy? J Immunother 35:651-660, 2012
10. Hinrichs CS, Spolski R, Paulos CM, et al: IL-2 and IL-21 confer opposing differentiation programs to CD8+ T cells for adoptive immunotherapy. Blood 111:5326-5333, 2008
11. Li Y, Bleakley M, Yee C: IL-21 influences the frequency, phenotype, and affinity of the antigen-specific CD8 T cell response. J Immunol 175:2261-2269, 2005
12. Li Y, Yee C: IL-21 mediated Foxp3 suppression leads to enhanced generation of antigen-specific CD8+ cytotoxic T lymphocytes. Blood 111:229-235, 2008
13. Cui W, Liu Y, Weinstein JS, et al: An interleukin-21-interleukin-10-STAT3 pathway is critical for functional maturation of memory CD8+ T cells. Immunity 35:792-805, 2011
14. Pollack SM, Jones RL, Farrar EA, et al: Tetramer guided, cell sorter assisted production of clinical grade autologous NY-ESO-1 specific CD8(+) T cells. J Immunother Cancer 2:36, 2014
15. Chen L: Co-inhibitory molecules of the B7-CD28 family in the control of T-cell immunity. Nat Rev Immunol 4:336-347, 2004
16. Sharma P, Wagner K, Wolchok JD, et al: Novel cancer immunotherapy agents with survival benefit: Recent successes and next steps. Nat Rev Cancer 11:805-812, 2011
17. Hodi FS, O'Day SJ, McDermott DF, et al: Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 363:711-723, 2010
18. Ribas A, Kefford R, Marshall MA, et al: Phase III randomized clinical trial comparing tremelimumab with standard-of-care chemotherapy in patients with advanced melanoma. J Clin Oncol 31:616-622, 2013
19. Robert C, Thomas L, Bondarenko I, et al: Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med 364:2517-2526, 2011
20. Thompson JA, Hamid O, Minor D, et al: Ipilimumab in treatmentnaive and previously treated patients with metastatic melanoma: Retrospective analysis of efficacy and safety data from a phase II trial. J Immunother 35:73-77, 2012
21. Prieto PA, Yang JC, Sherry RM, et al: CTLA-4 blockade with ipilimumab: Long-term follow-up of 177 patients with metastatic melanoma. Clin Cancer Res 18:2039-2047, 2012
22. Wolchok JD, Weber JS, Maio M, et al: Fouryear survival rates for patients with metastatic melanoma who received ipilimumab in phase II clinical trials. Ann Oncol 24:2174-2180, 2013
23. Ribas A, Timmerman JM, Butterfield LH, et al: Determinant spreading and tumor responses after peptide-based cancer immunotherapy. Trends Immunol 24:58-61, 2003
24. Kvistborg P, Philips D, Kelderman S, et al: Anti-CTLA-4 therapy broadens the melanoma-reactive CD8+ T cell response. Sci Transl Med 6:254ra128, 2014
25. Balch CM, Gershenwald JE, Soong SJ, et al: Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol 27:6199-6206, 2009
26. Kawakami Y, Eliyahu S, Sakaguchi K, et al: Identification of the immunodominant peptides of the MART-1 human melanoma antigen recognized by the majority of HLA-A2-restricted tumor infiltrating lymphocytes. J Exp Med 180:347-352, 1994
27. National Cancer Institute, National Institutes of Health: Common Terminology Criteria for Adverse Events (CTCAE), Version 4.0. http://evs.nci.nih.gov/ftp1/CTCAE/CTCAE-4.03-2010-06-14-QuickReference-5x7.pdf
28. Eisenhauer EA, Therasse P, Bogaerts J, et al: New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). Eur J Cancer 45:228-247, 2009
29. Wolchok JD, Hoos A, O'Day S, et al: Guidelines for the evaluation of immune therapy activity in solid tumors: Immunerelated response criteria. Clin Cancer Res 15:7412-7420, 2009
30. Liao X, Li Y, Bonini C, et al: Transfection of RNA encoding tumor antigens following maturation of dendritic cells leads to prolonged presentation of antigen and the generation of high-affinity tumorreactive cytotoxic T lymphocytes. Mol Ther 9:757-764, 2004
31. Weber JS, Kähler KC, Hauschild A: Management of immune-related adverse events and kinetics of response with ipilimumab. J Clin Oncol 30: 2691-2697, 2012
32. Ribas A, Hodi FS, Callahan M, et al: Hepatotoxicity with combination of vemurafenib and ipilimumab. N Engl J Med 368:1365-1366, 2013
33. Harding JJ, Pulitzer M, Chapman PB: Vemurafenib sensitivity skin reaction after ipilimumab. N Engl J Med 366:866-868, 2012
34. Ho WY, Nguyen HN, Wolfl M, et al: In vitro methods for generating CD8+ T-cell clones for immunotherapy from the naïve repertoire. J Immunol Methods 310:40-52, 2006
35. Ransohoff RM, Engelhardt B: The anatomical and cellular basis of immune surveillance in the central nervous system. Nat Rev Immunol 12: 623-635, 2012
36. Ragheb JA, Deen M, Schwartz RH: CD28-Mediated regulation of mRNA stability requires sequences within the coding region of the IL-2 mRNA. J Immunol 163:120-129, 1999
37. Topp MS, Riddell SR, Akatsuka Y, et al: Restoration of CD28 expression in CD28-CD8+ memory effector T cells reconstitutes antigen-induced IL-2 production. J Exp Med 198:947-955, 2003
38. Scholzen T, Gerdes J: The Ki-67 protein: from the known and the unknown. J Cell Physiol 182: 311-322, 2000
39. Butler MO, Friedlander P, Milstein MI, et al: Establishment of antitumor memory in humans using in vitro-educated CD8+ T cells. Sci Transl Med 3: 80ra34, 2011
40. McAdam AJ, Schweitzer AN, Sharpe AH: The role of B7 co-stimulation in activation and differentiation of CD4+ and CD8+ T cells. Immunol Rev 165: 231-247, 1998
41. + T cell homeostasis to promote cell survival instead of cell death. Nat Immunol 14: 143-151, 2013
42. Kaech SM, Wherry EJ, Ahmed R: Effector and memory T-cell differentiation: Implications for vaccine development. Nat Rev Immunol 2:251-262, 2002
43. Bernsen MR, Håkansson L, Gustafsson B, et al: On the biological relevance of MHC class II and B7 expression by tumour cells in melanoma metastases. Br J Cancer 88:424-431, 2003
44. Hersey P, Si Z, Smith MJ, et al: Expression of the co-stimulatory molecule B7 on melanoma cells. Int J Cancer 58:527-532, 1994
45. Robert L, Tsoi J, Wang X, et al: CTLA4 blockade broadens the peripheral T-cell receptor repertoire. Clin Cancer Res 20:2424-2432, 2014
46. Schreiber RD, Old LJ, Smyth MJ: Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion. Science 331: 1565-1570, 2011
47. Chandran SS, Paria BC, Srivastava AK, et al: Persistence of CTL clones targeting melanocyte differentiation antigens was insufficient to mediate significant melanoma regression in humans. Clin Cancer Res 21:534-543, 2015
48. Wolchok JD, Kluger H, Callahan MK, et al: Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med 369:122-133, 2013
49. + tumor-reactive repertoire infiltrating human tumors. J Clin Invest 124: 2246-2259, 2014